| Symbol | TCRT |
|---|---|
| Name | ALAUNOS THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 8030 EL RIO STREET,NAVY YARD PLAZA, HOUSTON, Texas, 77054, United States |
| Telephone | +1 346 355-4099 |
| Fax | — |
| — | |
| Website | https://www.alaunos.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001107421 |
| Description | Ziopharm Oncology Inc is registered with the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Ziopharm Oncology Inc is primarely in the business of pharmaceutical preparations. For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Ziopharm Oncology Inc. ZIOPHARM Oncology Inc is a biotechnology company that acquires, develops, and commercializes cancer therapies. Its preclinical and clinical pipeline focuses on treating hematological and solid tumor malignancies using cellular therapeutics. Ziopharm engages in gene therapy systems with its partner Intrexon and collaborators at the University of Texas. To fund the development of its product candidates, the company engages in contractual arrangements with licensing partners both in the United States and abroad. Additional info from NASDAQ: |
Weis Holger 🟢 acquired 3.9K shares of Alaunos Therapeutics, Inc. (TCRT) at $2.26 Transaction Date: Jun 30, 2026 | Filing ID: 295004
Read moreAlaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study
Read more(10% Negative) ALAUNOS THERAPEUTICS, INC. (TCRT) Announces Delay in adjustment Trials for body fat percentage Due to Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreWeis Holger 🟢 acquired 7.8K shares of Alaunos Therapeutics, Inc. (TCRT) at $2.26 Transaction Date: Jun 17, 2026 | Filing ID: 274305
Read moreWeis Holger 🟢 acquired 3.7K shares of Alaunos Therapeutics, Inc. (TCRT) at $2.37 Transaction Date: May 22, 2026 | Filing ID: 241999
Read moreAlaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies
Read more(10% Negative) ALAUNOS THERAPEUTICS, INC. (TCRT) Announces Clinical Trial Timeline Adjustment
Read moreAlaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models
Read moreVieser Jaime 🟢 acquired 6.5K shares of Alaunos Therapeutics, Inc. (TCRT) at $2.59 Transaction Date: Apr 29, 2026 | Filing ID: 201557
Read morePostma Robert W 🟢 acquired 6.3K shares of Alaunos Therapeutics, Inc. (TCRT) at $2.59 Transaction Date: Apr 29, 2026 | Filing ID: 201489
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05292859 | Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the… | — | Gynecologic Cancer | Completed | 2023-03-01 | 2025-05-30 | ClinicalTrials.gov |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Su… | Phase1 | Gynecologic Cancer | Terminated | 2022-04-04 | 2023-08-14 | ClinicalTrials.gov |
| NCT05124743 | HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous… | — | Ovarian Cancer | Terminated | 2021-09-24 | 2023-08-14 | ClinicalTrials.gov |
| NCT04006119 | Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects W… | Phase2 | Glioblastoma | Terminated | 2019-08-01 | 2021-08-05 | ClinicalTrials.gov |
| NCT03679754 | Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressi… | Phase1 | Glioblastoma | Completed | 2018-09-05 | 2021-01-19 | ClinicalTrials.gov |
| NCT03636477 | A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjec… | Phase1 | Glioblastoma | Completed | 2018-06-18 | 2021-06-30 | ClinicalTrials.gov |
| NCT03330197 | A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors In… | Phase1 | Pediatric Brain Tumor | Terminated | 2017-09-26 | 2021-09-10 | ClinicalTrials.gov |
| NCT02423902 | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer | Phase1 | Metastatic Breast Cancer | Terminated | 2015-07-18 | 2016-07-19 | ClinicalTrials.gov |
| NCT02026271 | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malign… | Phase1 | Glioblastoma Multiforme | Completed | 2015-06-01 | 2019-08-01 | ClinicalTrials.gov |
| NCT01703754 | Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With… | Phase2 | Breast Cancer Nos Metastatic Recurrent | Terminated | 2013-04-04 | 2014-08-07 | ClinicalTrials.gov |
| NCT01808534 | Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors | Phase2 | Adult Central Nervous System Germ Cell Tumor | Terminated | 2013-02-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT01555710 | Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Ch… | Phase3 | Extensive-Stage Small Cell Lung Cancer | Unknown | 2012-05-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01492036 | Long-Term Follow-Up of Recipient of Gene Transfer Research | — | Retroviridae Infections | Recruiting | 2011-12-09 | 2027-12-31 | ClinicalTrials.gov |
| NCT01397708 | Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination W… | Phase1 | Melanoma | Completed | 2011-08-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT00968760 | CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies | Phase1 | Lymphoma | Completed | 2011-06-20 | 2020-04-23 | ClinicalTrials.gov |
| NCT01340547 | Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-age… | Phase1 | Advanced Solid Tumors | Unknown | 2011-06-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01242072 | Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in… | Phase1 | Malignancy | Unknown | 2010-11-01 | 2012-12-01 | ClinicalTrials.gov |
| NCT01168791 | Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Fr… | Phase3 | Soft Tissue Sarcoma | Completed | 2010-07-01 | 2013-03-01 | ClinicalTrials.gov |
| NCT01139359 | Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin,… | Phase1 | Lymphoma | Withdrawn | 2010-06-01 | 2011-06-01 | ClinicalTrials.gov |
| NCT01139346 | Study of Oral Darinaparsin in Patients With Advanced Solid Tumors | Phase1 | Advanced Solid Tumors | Completed | 2010-06-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT01113970 | Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Brea… | Phase1 | Metastatic Breast Cancer | Unknown | 2010-03-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT00815607 | Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or … | Phase1 | Melanoma | Completed | 2009-04-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT00718484 | A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectab… | Phase2 | Soft Tissue Sarcoma | Unknown | 2008-08-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT00726687 | Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid … | Phase1 | Advanced Solid Tumors | Unknown | 2008-06-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00607711 | Study of Oral Palifosfamide Tris in Solid Tumors | Phase1 | Advanced Cancer | Suspended | 2008-03-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00608803 | Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors | Phase1 | Advanced Cancer | Completed | 2008-01-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00591383 | Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumo… | Phase1 | Advanced Solid Tumors | Unknown | 2008-01-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00592163 | Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas | Phase1 | Advanced Solid Tumors | Unknown | 2007-12-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00591890 | Phase IB Study of Indibulin Using Positron-Emission Tomography (PET) Scans | Phase1 | Advanced Cancer | Completed | 2007-10-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00591422 | Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-… | Phase1 | Advanced Cancer | Unknown | 2007-08-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00591292 | Phase I Study in Advanced Solid Tumors | Phase1 | Solid Tumors | Unknown | 2007-06-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT00423306 | A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma | Phase2 | HEPATOCELLULAR CARCINOMA | Unknown | 2007-01-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00423644 | A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b | Phase2 | Multiple Myeloma | Unknown | 2007-01-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00421213 | Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers | Phase2 | Hematologic Neoplasms | Completed | 2006-12-01 | 2012-04-01 | ClinicalTrials.gov |
| NCT00421135 | A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard… | Phase1 | Advanced Cancer | Completed | 2006-02-01 | 2007-10-01 | ClinicalTrials.gov |
| NCT00439686 | Study of ZIO-201 in Advanced Sarcoma | Phase1 | Advanced Sarcoma | Completed | 2006-02-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00303199 | Study of ZIO-101 in Multiple Myeloma | Phase1 | Multiple Myeloma | Completed | 2006-01-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00591396 | A Phase I Trial of ZIO-101 in Solid Tumors | Phase1 | Solid Tumors | Completed | 2005-07-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00509782 | Phase I Trial of ZIO-101 in Patients With Solid Tumors | Phase1 | Solid Tumors | Completed | 2005-05-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00592046 | A Phase I Trial of ZIO-101 in Hematologic Cancers | Phase1 | Acute Leukemia | Completed | 2005-05-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00591136 | Phase I Study of Indibulin in Patients With Solid Tumors | Phase1 | Solid Tumors | Completed | 2003-04-01 | 2008-09-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Questionnaires | Other | Preclinical | Retroviridae Infections | RECRUITING | NCT01492036 |
| Blood Tests | Other | Preclinical | Retroviridae Infections | RECRUITING | NCT01492036 |
| palifosfamide-tris | Other | Phase PHASE1 | Malignancy | UNKNOWN | NCT01242072 |
| CHOP | Other | Phase PHASE1 | Lymphoma | WITHDRAWN | NCT01139359 |
| darinaparsin | Other | Phase PHASE1 | Lymphoma | WITHDRAWN | NCT01139359 |
| darinaparsin | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT01139346 |
| Indibulin | Other | Phase PHASE1 | Metastatic Breast Cancer | UNKNOWN | NCT01113970 |
| Etoposide | Other | Phase PHASE3 | Extensive-Stage Small Cell Lung Cancer | UNKNOWN | NCT01555710 |
| Palifosfamide-tris | Other | Phase PHASE3 | Extensive-Stage Small Cell Lung Cancer | UNKNOWN | NCT01555710 |
| Carboplatin | Other | Phase PHASE3 | Extensive-Stage Small Cell Lung Cancer | UNKNOWN | NCT01555710 |
| Normal Saline | Other | Phase PHASE1 | Advanced Solid Tumors | UNKNOWN | NCT01340547 |
| palifosfamide-tris | Other | Phase PHASE1 | Advanced Solid Tumors | UNKNOWN | NCT01340547 |
| doxorubicin in combination with placebo | Other | Phase PHASE3 | Soft Tissue Sarcoma | COMPLETED | NCT01168791 |
| doxorubicin in combination with palifosfamide-tris | Other | Phase PHASE3 | Soft Tissue Sarcoma | COMPLETED | NCT01168791 |
| palifosfamide | Other | Phase PHASE2 | Adult Central Nervous System Germ Cell Tumor | TERMINATED | NCT01808534 |
| Melphalan | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00968760 |
| Cytarabine | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00968760 |
| Etoposide | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00968760 |
| Carmustine | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00968760 |
| IL-2 | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00968760 |
| CD19-specific T Cell Infusion | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00968760 |
| Stem Cell Transplant | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00968760 |
| Leukapheresis | Other | Phase PHASE1 | Lymphoma | COMPLETED | NCT00968760 |
| veledimex | Other | Phase PHASE1 | Glioblastoma Multiforme | COMPLETED | NCT02026271 |
| Ad-RTS-hIL-12 | Other | Phase PHASE1 | Glioblastoma Multiforme | COMPLETED | NCT02026271 |
| Cemiplimab-Rwlc | Other | Phase PHASE2 | Glioblastoma | TERMINATED | NCT04006119 |
| Veledimex | Other | Phase PHASE2 | Glioblastoma | TERMINATED | NCT04006119 |
| Ad-RTS-hIL-12 | Other | Phase PHASE2 | Glioblastoma | TERMINATED | NCT04006119 |
| Neoantigen specific TCR-T cell drug product | Drug | Preclinical | Gynecologic Cancer | COMPLETED | NCT05292859 |
| Nivolumab | Other | Phase PHASE1 | Glioblastoma | COMPLETED | NCT03636477 |
| veledimex | Other | Phase PHASE1 | Glioblastoma | COMPLETED | NCT03636477 |
| Ad-RTS-hIL-12 | Other | Phase PHASE1 | Glioblastoma | COMPLETED | NCT03636477 |
| Oral Veledimex - Arm 2 (DIPG) | Other | Phase PHASE1 | Pediatric Brain Tumor | TERMINATED | NCT03330197 |
| Oral Veledimex - Arm 1 (Pediatric Brain Tumor) | Other | Phase PHASE1 | Pediatric Brain Tumor | TERMINATED | NCT03330197 |
| Ad-RTS-hIL-12 | Other | Phase PHASE1 | Pediatric Brain Tumor | TERMINATED | NCT03330197 |
| veledimex | Other | Phase PHASE1 | Glioblastoma | COMPLETED | NCT03679754 |
| Ad-RTS-hIL-12 | Other | Phase PHASE1 | Glioblastoma | COMPLETED | NCT03679754 |
| Veledimex | Other | Phase PHASE1 | Metastatic Breast Cancer | TERMINATED | NCT02423902 |
| Ad-RTS-hIL-12 | Other | Phase PHASE1 | Metastatic Breast Cancer | TERMINATED | NCT02423902 |
| Palifosfamide | Other | Phase PHASE2 | Breast Cancer Nos Metastatic Recurrent | TERMINATED | NCT01703754 |
| Ad-RTS-hIL-12 and Veledimex | Other | Phase PHASE2 | Breast Cancer Nos Metastatic Recurrent | TERMINATED | NCT01703754 |
| INXN-1001 | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT01397708 |
| INXN-2001 | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT01397708 |
| Aldesleukin (IL-2) | Other | Phase PHASE1 | Gynecologic Cancer | TERMINATED | NCT05194735 |
| Neoantigen specific TCR-T cell drug product | Drug | Phase PHASE1 | Gynecologic Cancer | TERMINATED | NCT05194735 |
| Questionnaires | Other | Preclinical | Retroviridae Infections | RECRUITING | NCT01492036 |
| Blood Tests | Other | Preclinical | Retroviridae Infections | RECRUITING | NCT01492036 |
| Aldesleukin (IL-2) | BIOLOGICAL | Phase PHASE1 | Gynecologic Cancer | TERMINATED | NCT05194735 |
| Neoantigen specific TCR-T cell drug product | BIOLOGICAL | Preclinical | Gynecologic Cancer | COMPLETED | NCT05292859 |
| Cemiplimab-Rwlc | DRUG | Phase PHASE2 | Glioblastoma | TERMINATED | NCT04006119 |
| Nivolumab | DRUG | Phase PHASE1 | Glioblastoma | COMPLETED | NCT03636477 |
| Oral Veledimex - Arm 2 (DIPG) | DRUG | Phase PHASE1 | Pediatric Brain Tumor | TERMINATED | NCT03330197 |
| Oral Veledimex - Arm 1 (Pediatric Brain Tumor) | DRUG | Phase PHASE1 | Pediatric Brain Tumor | TERMINATED | NCT03330197 |
| Veledimex | DRUG | Phase PHASE2 | Glioblastoma | TERMINATED | NCT04006119 |
| veledimex | DRUG | Phase PHASE1 | Glioblastoma | COMPLETED | NCT03679754 |
| Ad-RTS-hIL-12 | BIOLOGICAL | Phase PHASE2 | Glioblastoma | TERMINATED | NCT04006119 |
| palifosfamide | DRUG | Phase PHASE2 | Adult Central Nervous System Germ Cell Tumor | TERMINATED | NCT01808534 |
| Palifosfamide | DRUG | Phase PHASE2 | Breast Cancer Nos Metastatic Recurrent | TERMINATED | NCT01703754 |
| Ad-RTS-hIL-12 and Veledimex | GENETIC | Phase PHASE2 | Breast Cancer Nos Metastatic Recurrent | TERMINATED | NCT01703754 |
| Palifosfamide-tris | DRUG | Phase PHASE3 | Extensive-Stage Small Cell Lung Cancer | UNKNOWN | NCT01555710 |
| Carboplatin | DRUG | Phase PHASE3 | Extensive-Stage Small Cell Lung Cancer | UNKNOWN | NCT01555710 |
| Questionnaires | BEHAVIORAL | Preclinical | Retroviridae Infections | RECRUITING | NCT01492036 |
| Blood Tests | OTHER | Preclinical | Retroviridae Infections | RECRUITING | NCT01492036 |
| INXN-2001 | BIOLOGICAL | Phase PHASE1 | Melanoma | COMPLETED | NCT01397708 |
| Normal Saline | DRUG | Phase PHASE1 | Advanced Solid Tumors | UNKNOWN | NCT01340547 |
| palifosfamide-tris | DRUG | Phase PHASE1 | Advanced Solid Tumors | UNKNOWN | NCT01340547 |
| doxorubicin in combination with placebo | DRUG | Phase PHASE3 | Soft Tissue Sarcoma | COMPLETED | NCT01168791 |
| doxorubicin in combination with palifosfamide-tris | DRUG | Phase PHASE3 | Soft Tissue Sarcoma | COMPLETED | NCT01168791 |
| CHOP | DRUG | Phase PHASE1 | Lymphoma | WITHDRAWN | NCT01139359 |
| darinaparsin | DRUG | Phase PHASE1 | Lymphoma | WITHDRAWN | NCT01139359 |
| Indibulin | DRUG | Phase PHASE1 | Metastatic Breast Cancer | UNKNOWN | NCT01113970 |
| Melphalan | DRUG | Phase PHASE1 | Lymphoma | COMPLETED | NCT00968760 |
| Cytarabine | DRUG | Phase PHASE1 | Lymphoma | COMPLETED | NCT00968760 |
| Etoposide | DRUG | Phase PHASE3 | Extensive-Stage Small Cell Lung Cancer | UNKNOWN | NCT01555710 |
| Carmustine | DRUG | Phase PHASE1 | Lymphoma | COMPLETED | NCT00968760 |
| IL-2 | DRUG | Phase PHASE1 | Lymphoma | COMPLETED | NCT00968760 |
| CD19-specific T Cell Infusion | PROCEDURE | Phase PHASE1 | Lymphoma | COMPLETED | NCT00968760 |
| Stem Cell Transplant | PROCEDURE | Phase PHASE1 | Lymphoma | COMPLETED | NCT00968760 |
| Leukapheresis | PROCEDURE | Phase PHASE1 | Lymphoma | COMPLETED | NCT00968760 |
| INXN-3001 | BIOLOGICAL | Phase PHASE1 | Melanoma | COMPLETED | NCT00815607 |
| INXN-1001 | DRUG | Phase PHASE1 | Melanoma | COMPLETED | NCT01397708 |
| capecitabine | DRUG | Phase PHASE1 | Advanced Solid Tumors | UNKNOWN | NCT00726687 |
| Doxorubicin | DRUG | Phase PHASE2 | Soft Tissue Sarcoma | UNKNOWN | NCT00718484 |
| Palifosfamide Tris and Doxorubicin | DRUG | Phase PHASE2 | Soft Tissue Sarcoma | UNKNOWN | NCT00718484 |
| ZIO-201-T and doxorubicin | DRUG | Phase PHASE1 | Advanced Cancer | COMPLETED | NCT00608803 |
| oral palifosfamide tris | DRUG | Phase PHASE1 | Advanced Cancer | SUSPENDED | NCT00607711 |
| ZIO-101-C (Darinaparsin) | DRUG | Phase PHASE1 | Advanced Solid Tumors | UNKNOWN | NCT00592163 |
| erlotinib | DRUG | Phase PHASE1 | Advanced Solid Tumors | UNKNOWN | NCT00591383 |
| indibulin | DRUG | Phase PHASE1 | Advanced Solid Tumors | UNKNOWN | NCT00726687 |
| ZIO-101 | DRUG | Phase PHASE1 | Solid Tumors | COMPLETED | NCT00509782 |
| Darinaparson | DRUG | Phase PHASE2 | Multiple Myeloma | UNKNOWN | NCT00423644 |
| Darinaparsin | DRUG | Phase PHASE2 | HEPATOCELLULAR CARCINOMA | UNKNOWN | NCT00423306 |
| ZIO-201 | DRUG | Phase PHASE1 | Advanced Sarcoma | COMPLETED | NCT00439686 |
| ZIO-101 (Darinaparsin) | DRUG | Phase PHASE1 | Acute Leukemia | COMPLETED | NCT00592046 |